Classification of lung adenocarcinoma based on senescence-related genes identifies a cluster with immunotherapy resistance and poor prognosis
Contact us if these videos are not relevant.
Contact us if these videos are not relevant.
View abstract on PubMed
Summary
This summary is machine-generated.Cellular senescence influences lung adenocarcinoma progression and immunotherapy resistance. A new risk score effectively predicts patient response to treatment, offering insights into overcoming resistance.
Area Of Science
- Oncology
- Immunology
- Genetics
Background
- Lung adenocarcinoma is a leading cause of cancer mortality.
- Immunotherapy is a crucial treatment, but resistance is common.
- Cellular senescence impacts tumor progression and the tumor microenvironment.
Purpose Of The Study
- To investigate the role of cellular senescence in lung adenocarcinoma.
- To identify patient clusters based on senescence-related gene expression.
- To develop a predictive model for immunotherapy response.
Main Methods
- Consensus clustering was used to classify patients based on senescence-related genes.
- Machine learning was applied to create a senescence-related risk score.
- The model's predictive ability was validated in training and validation cohorts.
Main Results
- Two patient clusters were identified with distinct immune characteristics.
- One cluster displayed immunosuppressive traits and immunotherapy resistance.
- A high senescence-related risk score correlated with poor survival and resistance.
Conclusions
- Cellular senescence is linked to immunotherapy resistance in lung adenocarcinoma.
- The senescence-related risk score shows potential for predicting treatment outcomes.
- Further research into senescence may uncover novel therapeutic strategies.
Contact us if these videos are not relevant.
Contact us if these videos are not relevant.
Related Concept Videos
Tumor progression is a phenomenon where the pre-formed tumor acquires successive mutations to become clinically more aggressive and malignant. In the 1950s, Foulds first described the stepwise progression of cancer cells through successive stages.
Colon cancer is one of the best-documented examples of tumor progression. Early mutation in the APC gene in colon cells causes a small growth on the colon wall called a polyp. With time, this polyp grows into a benign, pre-cancerous tumor. Further...
Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
Genes usually encode proteins necessary for the proper functioning of a healthy cell. Mutations can often cause changes to the gene expression pattern, thereby altering the phenotype.
When the function of certain critical genes, especially those involved in cell cycle regulation and cell growth signaling cascades, gets disrupted, it upsets the cell cycle progression. Such cells with unchecked cell cycles start proliferating uncontrollably and eventually develop into tumors.
Such genes that act...
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...